The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients

• Main Authors: Teun van Gelder (Author), Soufian Meziyerh (Author), Jesse J. Swen (Author), Aiko P. J. de Vries (Author), Dirk Jan A. R. Moes (Author)
• 格式: 圖書
• 出版: Frontiers Media S.A., 2020-07-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

Tacrolimus is metabolized by CYP3A4 and CYP3A5 enzymes. Patients expressing CYP3A5 (in Caucasian patients about 15% of the population but more frequent in African Americans and Asians) have a dose requirement that is around 50% higher than non-expressers to reach the target concentration. CYP3A5 exp...